Asset Management One Co. Ltd. Purchases 2,176 Shares of MEDNAX Inc (MD)

Asset Management One Co. Ltd. raised its position in MEDNAX Inc (NYSE:MD) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 152,185 shares of the company’s stock after purchasing an additional 2,176 shares during the quarter. Asset Management One Co. Ltd. owned 0.16% of MEDNAX worth $6,562,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. raised its stake in shares of MEDNAX by 0.3% in the 2nd quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after purchasing an additional 28,155 shares during the period. Vanguard Group Inc. increased its position in shares of MEDNAX by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after acquiring an additional 38,645 shares during the last quarter. Thompson Siegel & Walmsley LLC increased its position in shares of MEDNAX by 19.7% in the third quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after acquiring an additional 428,184 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of MEDNAX by 22.6% in the second quarter. Victory Capital Management Inc. now owns 2,423,865 shares of the company’s stock valued at $146,329,000 after acquiring an additional 446,074 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in shares of MEDNAX by 4.8% in the third quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after acquiring an additional 106,883 shares during the last quarter. 98.43% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at $1,834,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of MEDNAX stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the transaction, the director now owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

MEDNAX Inc (MD) opened at $51.41 on Tuesday. MEDNAX Inc has a 1-year low of $40.56 and a 1-year high of $72.13. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $4,785.78, a PE ratio of 15.63, a P/E/G ratio of 1.65 and a beta of 0.40.

MEDNAX (NYSE:MD) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting analysts’ consensus estimates of $0.87. MEDNAX had a return on equity of 10.80% and a net margin of 7.76%. The business had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. During the same quarter last year, the company posted $1.09 earnings per share. MEDNAX’s quarterly revenue was up 4.9% on a year-over-year basis. analysts forecast that MEDNAX Inc will post 3.1 EPS for the current fiscal year.

MD has been the topic of a number of recent research reports. Robert W. Baird reaffirmed a “hold” rating and issued a $47.00 target price on shares of MEDNAX in a research report on Sunday, September 3rd. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Piper Jaffray Companies initiated coverage on MEDNAX in a research report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 target price on the stock. KeyCorp set a $51.00 target price on MEDNAX and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets initiated coverage on MEDNAX in a research report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $53.70.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://sportsperspectives.com/2017/12/19/asset-management-one-co-ltd-purchases-2176-shares-of-mednax-inc-md.html.

MEDNAX Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply